Two new medications manufactured by separate companies have gained FDA approval for treating irritable bowel syndrome with diarrhea (IBS-D) in adults.
One of the drugs, eluxadoline, which is marketed as Viberzi, activates receptors in the nervous system that can lessen bowel contractions. In 2 randomized, double-blind, placebo-controlled trials involving 2425 patients, eluxadoline was more effective than placebo in simultaneously reducing abdominal pain and improving stool consistency over 26 weeks of treatment. The most common adverse effects associated were constipation, nausea, and abdominal pain (http://1.usa.gov/1dAfFBH).
Voelker R. New Therapies for Irritable Bowel Syndrome. JAMA. 2015;314(1):17. doi:10.1001/jama.2015.6855